Clinical-Laboratory Effectiveness of Immune-Replacement Therapy of Hemorrhagic Fever with Renal Syndrome

Abstract

Currently, hemorrhagic fever with renal syndrome (HFRS) remains the most common natural focal disease of viral etiology in the Russian Federation. Effective antiviral drugs have not yet been developed. Pathogenetic and symptomatic drugs are mainly used in the treatment of HFRS.The aim of the study was to evaluate the clinical and laboratory effectiveness of intravenous gabriglobin in the treatment of moderate forms of HFRS.Materials and methods. The study included 22 patients with a diagnosis “HFRS of moderate severity” in the febrile stage of the disease. In the febrile period of HFRS, patients of the main group (n=10) were given gabriglobin via intravenous route at a dose of 0.1 g/kg per day along with pathogenetic therapy. The course of treatment was 2–3 infusions. The control group (n=12) received only pathogenetic therapy.Results and conclusions. As a result of the studies, the clinical and laboratory efficacy of intravenous administration of gabriglobin in the treatment of patients with moderate-grade HFRS was revealed, which was manifested by a decrease in the duration of the febrile period by 2.1 days, the severity of oliguria and a decrease in the duration of thrombocytopenia by 3.5 days compared with the group of patients receiving only pathogenetic therapy.

Keywords

• hemorrhagic fever with renal syndrome
• immuno-replacement therapy
• gabriglobin